BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

NCT00185211 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

468

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Interferon beta-1b (Betaseron, BAY86-5046)
DRUG: Interferon beta-1b (Betaseron, BAY86-5046)

Sponsor

Bayer